CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary

Article Oncology

The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

Janet K. Peper-Gabriel et al.

Summary: This study generated a PD-L1/4-1BB bispecific molecule, PRS-344/S095012, that combines checkpoint blockade with 4-1BB stimulation, increasing antitumor immunity and demonstrating strong antitumoral efficacy in a mouse model.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

Alvaro Teijeira et al.

Summary: In this study, the performance of the CEA-CD3 T cell bispecific antibody cibisatamab in three-dimensional tumor organoids cocultured with T cells was investigated using time-lapse confocal microscopy. The results showed that the killing of tumor cells was dependent on the levels of surface CEA expression, and the higher affinity CEACAM5-CD3 bispecific antibody remained active on low CEA expressing organoids. Additionally, the coculture of tumor organoids, autologous fibroblasts, and T cells demonstrated a costimulatory effect of anti-FAP-4-1BBL antibody, leading to enhanced tumor cell killing.

THERANOSTICS (2022)

添加到收藏夹

Review Immunology

Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing

Mark Gurney et al.

Summary: Genome engineered natural killer (NK) cell therapies show promise in cancer immunotherapy. The use of feeder cells and genome editing technologies can enhance the anti-tumor activity of NK cells, but there are still uncertainties and complexities in the interactions between these components.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

An Fc-inert PD-L1x4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation

Alexander Muik et al.

Summary: Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have changed the treatment paradigm for advanced solid tumors, but treatment resistance remains a challenge. Dual targeting of PD-L1 and 4-1BB with a bispecific antibody may provide a novel approach to improve PD-1/PD-L1 checkpoint blockade.

ONCOIMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Alexander Muik et al.

Summary: GEN1046 is a first-in-class bispecific immunotherapy agent that targets both the PD-L1 and 4-1BB pathways, leading to enhanced T-cell proliferation and antitumor immune response. It has demonstrated promising preclinical and early clinical activity, with manageable safety, especially in patients resistant to prior PD-(L)1 immunotherapy.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Oncology

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

Javier Glez-Vaz et al.

Summary: CD137 agonists have shown efficacy in tumor treatment, and the levels of sCD137 and CD137 surface expression can serve as quantitative parameters for therapeutic activity.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Immunology

Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer

David S. Hong et al.

Summary: This study aimed to estimate the objective response rate of utomilumab in patients with immune checkpoint inhibitor-refractory melanoma and non-small-cell lung cancer. The results showed that utomilumab had good tolerability but low antitumor activity. Efficacy was associated with immune-active tumor microenvironments.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity

Alexander Muik et al.

Summary: DuoBody-CD40x4-1BB is a novel antibody capable of enhancing antitumor immunity by modulating the functions of immune cells. In vitro and in vivo experiments have demonstrated its ability to enhance dendritic cell and T-cell functions, as well as its biological activity in patients with advanced solid tumors. These findings suggest that targeting CD40 and 4-1BB with an Fc-inert bispecific antibody may be an effective approach for cancer treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Immunology

Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells

B. Rhodes Ford et al.

Summary: The response rates to immunotherapy in solid tumors remain low due to the prevalence of terminally exhausted T cells. This study used CUT&RUN method to analyze the histone modification landscape of tumor-infiltrating CD8(+) T cells and found unexpected chromatin features in terminally exhausted T cells that limit their transcriptional potential. The study also linked increased histone bivalency to hypoxia exposure and showed that hypoxia-insensitive histone demethylase Kdm6b can increase cell function and promote antitumor immunity.

SCIENCE IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy

Alvaro Teijeira et al.

Summary: The study highlights the critical role of cDC1 dendritic cells in influencing the efficacy of immunotherapy regimens, with depletion of these cells impacting antitumor immune responses. Results show that the presence of functional cDC1 cells at the initiation of immunotherapy is crucial for successful treatment of established tumors.

CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in mice

Aya Sugyo et al.

Translational Oncology (2022)

添加到收藏夹

Article Oncology

Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation

Mika Kamata-Sakurai et al.

Summary: The novel anti-CD137 switch antibody STA551 shows strong and broad antitumor efficacy by targeting extracellular ATP in the tumor microenvironment, providing a potential treatment option for a wide variety of cancers regardless of antigen expression. The antibody demonstrates potent tumor inhibition without systemic toxicity or dependence on antigen expression in both mouse and human tumor models, supporting its further clinical testing and potential application to other cancer therapy targets.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

B7-H3x4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes

Gihoon You et al.

Summary: The bispecific antibody B7-H3x4-1BB effectively restricts 4-1BB stimulation in tumors and elicits a 4-1BB-dependent antitumor response, primarily targeting CD8 T cells for increased proliferation and cytokine production. Combination therapy with PD-1 blockade further enhances this antitumor activity by increasing terminally differentiated CD8 T cells, providing an effective and safe treatment option for B7-H3-positive cancers.

SCIENCE ADVANCES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Role of ADAM10 and ADAM17 in Regulating CD137 Function

Jana Seidel et al.

Summary: The study found that ADAM10 and potentially also ADAM17 play a central role in the generation of CD137. The production of soluble CD137 can be inhibited by blocking the interaction of ADAM10 with PS. Overexpression of ANO6 increases stimulated shedding and results in maximal constitutive shedding of CD137.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Oncology

Paradigms on Immunotherapy Combinations with Chemotherapy

Diego Salas-Benito et al.

Summary: Checkpoint inhibitors are being added to standard-of-care chemotherapy in clinical trials with success reported in various cancer types, but chemotherapy regimens have not been optimized for these combinations; optimal approaches to chemo-immunotherapy should include neoadjuvant and adjuvant schemes to maximize the benefits of both treatments.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

Itziar Otano et al.

Summary: This study demonstrates that providing CD137 costimulation in-cis with the TCR-CD3-ligating cell is more effective in promoting T cell activation, proliferation, survival, and function compared to providing it in-trans. This finding is important for understanding the immunotherapeutic effects of CAR T cells and CD137 agonistic therapies currently in clinical trials.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity

Marta Compte et al.

Summary: The researchers developed a humanized EGFR-specific 4-1BB-agonistic trimerbody, which showed significant antitumor activity in a wide range of human tumors without hepatotoxicity. Combining the trimerbody with a PD-L1 blocker led to increased IFN gamma secretion and resulted in tumor regression in aggressive triple-negative breast cancer humanized mice.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

Mariona Cabo et al.

Summary: This study demonstrates that CD137 costimulation can overcome TGFβ-mediated inhibition of NK cell antitumor responses, promoting NK cell proliferation and function, as well as enhancing direct and antibody-dependent cytotoxicity against tumors.

CANCER IMMUNOLOGY RESEARCH (2021)

添加到收藏夹

Article Oncology

BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism

Kristen Hurov et al.

Summary: The study developed a tumor-targeted CD137 agonist BT7480 that binds to Nectin-4 and CD137, resulting in potent tumor-specific immune cell activation, showing potential therapeutic effects in human cancers.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Meeting Abstract Oncology

M9657, A NOVEL TUMOR-TARGETED CONDITIONAL ANTI-CD137 AGONIST DISPLAYS MSLN-DEPENDENT ANTI-TUMOR IMMUNITY

Chunxiao Xu et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells

Nathan Singh et al.

Summary: The study found CD22 to be an alternative immunotherapy target in ALL, with the pilot clinical trials of 4-1BB-based CAR T cells targeting CD22 showing unexpectedly low response rates. It highlights the beneficial role of autonomous signaling in CAR function and demonstrates the utility of bedside-to-bench-to-bedside translation in designing and implementing CAR T cell therapies.

NATURE MEDICINE (2021)

添加到收藏夹

Review Oncology

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains

Kathryn M. Cappell et al.

Summary: CAR T cell therapies targeting haematological malignancies show promising efficacy, with CD28- and 4-1BB-derived costimulatory domains demonstrating potentially different cellular and clinical effects. Further research is needed to compare their effectiveness and toxicity profiles.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

Inaki Etxeberria et al.

Summary: CD137 costimulation enhances antitumor immunity, and a protease-activated prodrug form of anti-CD137 antibody shows selective activation in the tumor microenvironment, providing therapeutic opportunities for tumor treatment.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A human CD137xPD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade

Cecile Geuijen et al.

Summary: Researchers have discovered a human CD137xPD-L1 bispecific antibody, MCLA-145, which potently activates T cells at sub-nanomolar concentrations and demonstrates low systemic toxicity in non-human primates. The conditional activation of CD137 signaling by MCLA-145 may provide both safety and potency advantages, enhancing anti-cancer activity.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

Novel anti-4-1BBxPD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

Seongju Jeong et al.

Summary: The novel anti-4-1BBxPD-L1 bispecific antibody, ABL503, shows promising biological activity in activating 4-1BB signaling in the context of PD-L1 and blocking PD-1/PD-L1 signaling. It enhances T-cell activation and reinvigorates tumor-infiltrating CD8(+) T cells, demonstrating superior anti-tumor activity with low risk of liver toxicity.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer

Tianhang Zhai et al.

Summary: A unique single-domain antibody targeting the CRD4 domain of 4-1BB was discovered in this study, which showed potent activation of 4-1BB and blockade of PD-L1 in cell-based assays. Incorporation of this antibody into a 4-1BB/PD-L1 bispecific (PM1003) resulted in potent inhibition of PD-L1 activity with minimal toxicity in vivo, making it a promising next generation therapeutic agent for cancer therapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade

Stefan Warmuth et al.

Summary: NM21-1480 is a tri-specific antibody-based molecule that targets tumor-infiltrating T cells, overcoming immune checkpoint resistance without causing liver toxicity. It shows promising pharmacokinetics and efficacy in preclinical studies.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Article Hematology

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma

John Timmerman et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

添加到收藏夹

Article Oncology

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Ajay K. Gopal et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Medicine, Research & Experimental

A conserved intratumoral regulatory T cell signature Identifies 4-1BB as a pan-cancer target

Zachary T. Freeman et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Enli Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models

Matthew A. Lakins et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling

Benjamin Philipson et al.

SCIENCE SIGNALING (2020)

添加到收藏夹

Article Oncology

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer

Marta Trub et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Meeting Abstract Oncology

A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies

G. Ku et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours

I. Melero et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Immunology

A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy

Shannon K. Oda et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

添加到收藏夹

Editorial Material Immunology

4-1BB (CD137) in anticancer chimeras

Ignacio Melero et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

添加到收藏夹

Meeting Abstract Hematology

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

Sylvia Herter et al.

BLOOD (2020)

添加到收藏夹

Meeting Abstract Hematology

Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma

Martin Hutchings et al.

BLOOD (2020)

添加到收藏夹

Article Allergy

Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency

Mohammed F. Alosaimi et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)

添加到收藏夹

Article Oncology

Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343

Marlon J. Hinner et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity

Xinyue Qi et al.

NATURE COMMUNICATIONS (2019)

添加到收藏夹

Article Oncology

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

Maria C. Ochoa et al.

ONCOIMMUNOLOGY (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Bispecific antibodies: a mechanistic review of the pipeline

Aran F. Labrijn et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

添加到收藏夹

Article Cell Biology

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Christina Claus et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Article Hematology

CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis

Ido Somekh et al.

BLOOD (2019)

添加到收藏夹

Article Immunology

Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells

Remy Rodriguez et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2019)

添加到收藏夹

Article Oncology

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma

Zhitao Ying et al.

MOLECULAR THERAPY-ONCOLYTICS (2019)

添加到收藏夹

Article Oncology

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells

Sakthi Rajendran et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

Paul J. Carter et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

添加到收藏夹

Article Oncology

CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes

M. Angela Aznar et al.

CANCER IMMUNOLOGY RESEARCH (2018)

添加到收藏夹

Article Oncology

Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB)

Arantza Azpilikueta et al.

ONCOIMMUNOLOGY (2018)

添加到收藏夹

Article Oncology

Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway

Todd Bartkowiak et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Oncology

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Neil H. Segal et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Immunology

4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses

Ashley V. Menk et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2018)

添加到收藏夹

Article Oncology

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma

Rene J. Tavera et al.

JOURNAL OF IMMUNOTHERAPY (2018)

添加到收藏夹

Review Biotechnology & Applied Microbiology

The promise and challenges of immune agonist antibody development in cancer

Patrick A. Mayes et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

添加到收藏夹

Article Oncology

Mitochondria! Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation

Alvaro Teijeira et al.

CANCER IMMUNOLOGY RESEARCH (2018)

添加到收藏夹

Article Immunology

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function

Sarah L. Buchan et al.

IMMUNITY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

Marta Compte et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Review Oncology

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

Michael M. Boyiadzis et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation

Sonia Guedan et al.

JCI INSIGHT (2018)

添加到收藏夹

Article Oncology

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Neil H. Segal et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression

Maria Parkhurst et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Immunology

Dichotomous Expression of TNF Superfamily Ligands on Antigen-Presenting Cells Controls Post-priming Anti-viral CD4+ T Cell Immunity

Yu-Han Chang et al.

IMMUNITY (2017)

添加到收藏夹

Article Immunology

The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment

Jason B. Williams et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2017)

添加到收藏夹

Article Immunology

CD137 Plays Both Pathogenic and Protective Roles in Type 1 Diabetes Development in NOD Mice

Matthew H. Forsberg et al.

JOURNAL OF IMMUNOLOGY (2017)

添加到收藏夹

Article Immunology

Intrinsic 4-1BB signals are indispensable for the establishment of an influenza-specific tissue-resident memory CD8 T-cell population in the lung

A. C. Zhou et al.

MUCOSAL IMMUNOLOGY (2017)

添加到收藏夹

Article Oncology

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Anthony W. Tolcher et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology

Qian Zhang et al.

CELL (2017)

添加到收藏夹

Article Cell Biology

Triple costimulation via CD80, 4-1BB, and CD83 ligand elicits the long-term growth of Vγ9Vδ2 T cells in low levels of IL-2

Hyun-Woo Cho et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2016)

添加到收藏夹

Article Oncology

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

Alfonso R. Sanchez-Paulete et al.

CANCER DISCOVERY (2016)

添加到收藏夹

Article Oncology

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism

Sara Labiano et al.

ONCOIMMUNOLOGY (2016)

添加到收藏夹

Review Oncology

Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies

M. F. Sanmamed et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Editorial Material Oncology

Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?

Bettina Weigelin et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)

添加到收藏夹

Article Oncology

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer

Jing Liu et al.

CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming

Maria E. Rodriguez-Ruiz et al.

CANCER RESEARCH (2016)

添加到收藏夹

Article Immunology

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

Omkar U. Kawalekar et al.

IMMUNITY (2016)

添加到收藏夹

Article Oncology

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies

Arantza Azpilikueta et al.

JOURNAL OF THORACIC ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

Jing Liu et al.

CANCER DISCOVERY (2016)

添加到收藏夹

Article Oncology

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice

Miguel F. Sanmamed et al.

CANCER RESEARCH (2015)

添加到收藏夹

Article Immunology

c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8+ memory T-cell survival

Maria Letizia Giardino Torchia et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2015)

添加到收藏夹

Article Oncology

Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21

Xiaomei Li et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2015)

添加到收藏夹

Review Medicine, Research & Experimental

Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future

Lieping Chen et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Adrienne H. Long et al.

NATURE MEDICINE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine

Todd Bartkowiak et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)

添加到收藏夹

Review Immunology

Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?

Byungsuk Kwon

IMMUNE NETWORK (2015)

添加到收藏夹

Review Oncology

Evolving synergistic combinations of targeted immunotherapies to combat cancer

Ignacio Melero et al.

NATURE REVIEWS CANCER (2015)

添加到收藏夹

Review Immunology

Orchestrating immune check-point blockade for cancer immunotherapy in combinations

Jose Luis Perez-Gracia et al.

CURRENT OPINION IN IMMUNOLOGY (2014)

添加到收藏夹

Article Medicine, Research & Experimental

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

Alena Gros et al.

JOURNAL OF CLINICAL INVESTIGATION (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

Zineb Belcaid et al.

PLOS ONE (2014)

添加到收藏夹

Editorial Material Oncology

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy

Huafeng Wei et al.

ONCOIMMUNOLOGY (2014)

添加到收藏夹

Article Oncology

Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model

Aizea Morales-Kastresana et al.

CLINICAL CANCER RESEARCH (2013)

添加到收藏夹

Article Oncology

Agonistic CD40 Antibodies and Cancer Therapy

Robert H. Vonderheide et al.

CLINICAL CANCER RESEARCH (2013)

添加到收藏夹

Article Immunology

4-1BB signal stimulates the activation, expansion, and effector functions of γδ T cells in mice and humans

Seung J. Lee et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2013)

添加到收藏夹

Article Immunology

T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63-Polyubiquitin-Dependent Signals from Endosomes

Ivan Martinez-Forero et al.

JOURNAL OF IMMUNOLOGY (2013)

添加到收藏夹

Article Immunology

GITR-Dependent Regulation of 4-1BB Expression: Implications for T Cell Memory and Anti-4-1BB-Induced Pathology

Gloria H. Y. Lin et al.

JOURNAL OF IMMUNOLOGY (2013)

添加到收藏夹

Article Cell Biology

Leukocyte-specific protein 1 links TNF receptor-associated factor 1 to survival signaling downstream of 4-1BB in T cells

Laurent Sabbagh et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy

Jessica Ann Chacon et al.

PLOS ONE (2013)

添加到收藏夹

Article Oncology

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

Timothy S. Fisher et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)

添加到收藏夹

Article Oncology

Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies

Inge Verbrugge et al.

CANCER RESEARCH (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

Opposing Roles for TRAF1 in the Alternative versus Classical NF-κB Pathway in T Cells

Ann J. McPherson et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2012)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Immunotherapeutic Synergy Between Anti-CD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12

Jose I. Quetglas et al.

MOLECULAR THERAPY (2012)

添加到收藏夹

Article Cell Biology

4-1BB/4-1BBL Interaction Promotes Obesity-Induced Adipose Inflammation by Triggering Bidirectional Inflammatory Signaling in Adipocytes/Macrophages

Thai Hien Tu et al.

MEDIATORS OF INFLAMMATION (2012)

添加到收藏夹

Article Oncology

The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy

Asis Palazon et al.

CANCER DISCOVERY (2012)

添加到收藏夹

Article Hematology

被撤回的出版物: CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies (Retracted article. See vol. 134, pg. 658, 2019)

Holbrook E. Kohrt et al.

BLOOD (2011)

添加到收藏夹

Article Oncology

Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes

Asis Palazon et al.

CANCER RESEARCH (2011)

添加到收藏夹

Article Oncology

Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function

Jessica Ann Hernandez-Chacon et al.

JOURNAL OF IMMUNOTHERAPY (2011)

添加到收藏夹

Review Cell Biology

CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction

Zhe Shao et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2011)

添加到收藏夹

Article Oncology

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

Juan Dubrot et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)

添加到收藏夹

Article Immunology

CD137 Promotes Proliferation and Survival of Human B Cells

Xiaoyu Zhang et al.

JOURNAL OF IMMUNOLOGY (2010)

添加到收藏夹

Article Immunology

CD137-Mediated Pathogenesis from Chronic Hepatitis to Hepatocellular Carcinoma in Hepatitis B Virus-Transgenic Mice

Jun Wang et al.

JOURNAL OF IMMUNOLOGY (2010)

添加到收藏夹

Article Biochemistry & Molecular Biology

Crystal Structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 Complexes: Affinity, Specificity, and Regulation

Chao Zheng et al.

MOLECULAR CELL (2010)

添加到收藏夹

Review Oncology

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

Paolo A. Ascierto et al.

SEMINARS IN ONCOLOGY (2010)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structural Basis for the Lack of E2 Interaction in the RING Domain of TRAF2

Qian Yin et al.

BIOCHEMISTRY (2009)

添加到收藏夹

Article Immunology

Endogenous 4-1BB Ligand Plays a Critical Role in Protection from Influenza-Induced Disease

Gloria H. Y. Lin et al.

JOURNAL OF IMMUNOLOGY (2009)

添加到收藏夹

Article Immunology

Hypercostimulation through 4-1BB Distorts Homeostasis of Immune Cells

Seung-Woo Lee et al.

JOURNAL OF IMMUNOLOGY (2009)

添加到收藏夹

Article Oncology

Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy

Young H. Kim et al.

MOLECULAR CANCER THERAPEUTICS (2009)

添加到收藏夹

Article Multidisciplinary Sciences

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

Carmine Carpenito et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

添加到收藏夹

Article Oncology

Combination therapy with cisplatin and anti-4-1BB: Synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity

Young H. Kim et al.

CANCER RESEARCH (2008)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune regulation and control of regulatory T cells by OX40 and 4-1BB

Takanori So et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2008)

添加到收藏夹

Article Oncology

Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice

Seong-A Ju et al.

INTERNATIONAL JOURNAL OF CANCER (2008)

添加到收藏夹

Article Immunology

ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo

Laurent Sabbagh et al.

JOURNAL OF IMMUNOLOGY (2008)

添加到收藏夹

Article Biochemistry & Molecular Biology

T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

Matthias T. Stephan et al.

NATURE MEDICINE (2007)

添加到收藏夹

Article Immunology

Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice

Liguo Niu et al.

JOURNAL OF IMMUNOLOGY (2007)

添加到收藏夹

Article Oncology

Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment

Yi Yang et al.

CANCER RESEARCH (2007)

添加到收藏夹

Article Hematology

CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype

Yuwen Zhu et al.

BLOOD (2007)

添加到收藏夹

Article Oncology

Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity

Ergun Kocak et al.

CANCER RESEARCH (2006)

添加到收藏夹

Article Biochemistry & Molecular Biology

Eradication of established tumors in mice by a combination antibody-based therapy

Tomoyasu Uno et al.

NATURE MEDICINE (2006)

添加到收藏夹

Article Oncology

Vaccination with dendritic cells pulsed with apoptotic tumors in combination with Anti-OX40 and Anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice

C Cuadros et al.

INTERNATIONAL JOURNAL OF CANCER (2005)

添加到收藏夹

Article Biochemistry & Molecular Biology

The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma

DP Xu et al.

GENE THERAPY (2005)

添加到收藏夹

Article Multidisciplinary Sciences

Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses

J Bukczynski et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)

添加到收藏夹

Article Immunology

Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance

JL Foell et al.

IMMUNOLOGY (2004)

添加到收藏夹

Article Immunology

The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells

GX Zheng et al.

JOURNAL OF IMMUNOLOGY (2004)

添加到收藏夹

Article Oncology

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines

F Ito et al.

CANCER RESEARCH (2004)

添加到收藏夹

Article Oncology

Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens

I Tirapu et al.

INTERNATIONAL JOURNAL OF CANCER (2004)

添加到收藏夹

Article Biochemistry & Molecular Biology

4-1BB-mediated immunotherapy of rheumatoid arthritis

SK Seo et al.

NATURE MEDICINE (2004)

添加到收藏夹

Review Immunology

Co-stimulatory members of the TNFR family: Keys to effective T-cell immunity?

M Croft

NATURE REVIEWS IMMUNOLOGY (2003)

添加到收藏夹

Article Immunology

Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model

HK Sytwu et al.

JOURNAL OF AUTOIMMUNITY (2003)

添加到收藏夹

Article Immunology

4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1

HW Lee et al.

JOURNAL OF IMMUNOLOGY (2002)

添加到收藏夹

Article Immunology

4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner

RE Miller et al.

JOURNAL OF IMMUNOLOGY (2002)

添加到收藏夹

Article Biochemistry & Molecular Biology

T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer

O Martinet et al.

GENE THERAPY (2002)

添加到收藏夹

Article Immunology

Cutting edge: expression of functional CD137 receptor by dendritic cells

RA Wilcox et al.

JOURNAL OF IMMUNOLOGY (2002)

添加到收藏夹

Article Biochemistry & Molecular Biology

Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB

ZM Ye et al.

NATURE MEDICINE (2002)

添加到收藏夹

Article Immunology

Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis

YL Sun et al.

JOURNAL OF IMMUNOLOGY (2002)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB

MV Maus et al.

NATURE BIOTECHNOLOGY (2002)

添加到收藏夹

Article Immunology

Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells

T Futagawa et al.

INTERNATIONAL IMMUNOLOGY (2002)

添加到收藏夹

Article Allergy

Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders

IVWM Heinisch et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation

SH Chen et al.

MOLECULAR THERAPY (2000)

添加到收藏夹

Article Oncology

Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: Long-term remission of liver metastases in a mouse model

O Martinet et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)

添加到收藏夹

CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary

相关参考文献